[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Polares Medical SA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,64,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100632738","efs-of-posterior-leaflet-replacement-to-reduce-mitral-regurgitation-united-states-100632738",false,"NCT07517588","EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States)","Early Feasibility Experience of Posterior Leaflet Replacement to Reduce Mitral Regurgitation Using the MRace Implant (United States)","EXPLORE-MRace","Inclusion Criteria:\n\n1. Patient has symptomatic moderate-to-severe to severe functional mitral regurgitation despite stable doses of maximally tolerated guideline directed medical therapy (GDMT) per the Local Heart Team.\n\n   Note: In the 30 days prior to performing screening assessments, no new GDMT medications should be introduced and current doses should be stable (i.e. no decrease of \\> 50% or increase of \\> 100%) excluding diuretics. Any changes beyond this range would not be considered stable GDMT.\n2. Functional MR graded 3+ or higher (using a scale of 0 to 4+) by transthoracic echocardiography (TTE) within 60 days prior to study procedure as evaluated by the sponsor's Echo Core Lab.\n3. New York Heart Association (NYHA) Functional Class II, III or ambulatory IV heart failure\n4. Patient must present with an STS Score less than 10% and deemed by the Local Heart Team to be at high risk but operable for mitral valve surgery.\n5. The Local Heart Team deems the patient unsuitable for commercially approved transcatheter mitral valve therapies\n6. 21 years of age or older\n7. Native mitral valve geometry and size is compatible with the Polares MRace system\n8. Anatomy is suitable for transfemoral transseptal access with the Polares MRace system\n9. Patient is willing to participate in study and provides signed IRB\u002FEC-approved informed consent\n10. Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits\n11. Patient is approved by an independent Patient Eligibility Committee\n\nExclusion Criteria:\n\n1. Echocardiographic parameters (any of the following, assessed by the Echo Core Lab)\n\n   1. Left ventricular ejection fraction (LVEF) \\\u003C 30%\n   2. Pulmonary artery systolic pressure (PASP) \\> 70mmHg or \\> 2\u002F3 SBP (Systolic Blood Pressure)\n   3. Left Ventricle End Diastolic Volume (LV EDV) \\> 200 mL\n   4. Left Ventricle End Systolic Volume (LV ESV) \\> 140 mL\n   5. Left Ventricle End Diastolic Diameter (LV EDD) \\> 70 mm\n   6. Left Ventricle End Systolic Diameter (LV ESD) \\> 55 mm\n2. Severe Right Ventricle (RV) dysfunction as per assessment by Local Heart Team or Eligibility Committee .\n3. Severe tricuspid regurgitation.\n4. Severe aortic stenosis or insufficiency.\n5. Severe mitral annulus calcification.\n6. Diseased mitral anterior and\u002For posterior leaflet, such as flail, \u002F prolapse, or\u002F heavy moderate to severe calcification.\n7. Barlow's disease.\n8. Presence of an implanted vena cava filter or any other device (e.g. ASD closure device) that may interfere with femoral vein access or delivery system access to the mitral valve.\n9. Contraindication for transesophageal echocardiography (TEE) or MDCT scan\n10. Active infection or endocarditis or infection requiring antibiotic therapy within 2 weeks of scheduled procedure.\n11. Previous mitral valve surgery or transcatheter mitral valve procedure.\n12. Prior orthotopic heart transplantation.\n13. Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus. History of deep vein thrombosis (DVT) or pulmonary embolism within 6 months of the index procedure.\n14. Untreated Class I indication for pacing (CRT). Implant or revision of any pacing device \\\u003C 30 days prior to intervention\n15. Any untreated clinically significant coronary artery disease requiring revascularization. Coronary, carotid, or endovascular artery disease treated percutaneously \\\u003C 30 days prior to study procedure. Cardiac surgery \\\u003C 90 days prior to study procedure.\n16. Myocardial infarction requiring intervention \\\u003C 30 days prior to study procedure\n17. Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis)\n18. Active peptic ulcer or upper gastrointestinal bleeding \\\u003C 90 days prior to study procedure.\n19. Stroke \\\u003C 180 days prior to study procedure.\n20. Severe COPD requiring oral steroid therapy or oxygen therapy.\n21. Severe renal insufficiency (creatinine \\> 3.0 mg\u002FdL) or patient requiring dialysis\n22. Cardiogenic shock at time of enrolment. Hemodynamic instability requiring inotropic support or mechanical heart assistance.\n23. Concurrent medical condition with a life expectancy of less than 2 years\n24. Pregnancy or breastfeeding at time of enrolment with a positive pregnancy test within 14 days of study procedure.\n25. History of bleeding diathesis or coagulopathy or leukopenia (WBC \\\u003C 3,000 mcL) or acute anemia (Hb \\\u003C 9 g\u002FdL) or thrombocytopenia (platelets \\\u003C 50,000 cells mcL)\n26. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated.\n\n    Note. Patient must be able to tolerate at least one antiplatelet medication AND one anticoagulant medication.\n27. Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial\u002Fprocedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments.\n28. Patient is in need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months.\n29. Company employees or their immediate family members.\n30. Patient is considered to be part of a vulnerable population, is under guardianship, or subject to any other medical, social or psychological conditions that preclude appropriate consent and follow-up.\n31. Patient is participating in another clinical study for which follow-up is currently ongoing.","ALL","21 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this early feasibility clinical trial is to learn if the device MR-ace Implant and Delivery System works in patients with moderate or severe mitral valve regurgitation. It will also learn about the safety of the device MR-ace Implant and Delivery System. The main questions it aims to answer are:\n\nDoes implanting the MR-ace device reduce the symptoms of mitral regurgitation? Does the device reduce the the leak through your mitral valve?\n\nParticipants will:\n\nBe implanted with the device Visit the clinic for checkups and tests at 30 days, 6 months, 12 months, and 2, 3, 4 and 5 years following your procedure Complete a quality of life survey",[27],"Mitral Regurgitation","NOT_YET_RECRUITING","2026-04-03",{"date":31,"type":32},"2026-04-08","ACTUAL",{"date":34,"type":21},"2026-06-01",{"date":36,"type":21},"2031-12-31",{"name":38,"class":39},"Polares Medical SA","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100524793","explore-mrace-early-feasibility-experience-of-posterior-leaflet-restoration-to-reduce-mitral-regurgitation-using-the-mrace-implant-100524793","NCT06113354","EXPLORE MRace: Early Feasibility Experience of Posterior Leaflet Restoration to Reduce Mitral Regurgitation Using the MRace Implant","Early Feasibility Experience of Posterior Leaflet Restoration to Reduce Mitral Regurgitation Using the MRace Implant (EXPLORE MRace)","EXPLORE MRace","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Greater than moderate mitral regurgitation (Grade 3+ or higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to study procedure\n3. Patient must present with an STS Score less than 10%\n4. High surgical risk for conventional mitral repair or replacement due to morphological criteria (e.g. leaflet or annulus calcifications), but operable, as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure\n5. New York Heart Association (NYHA) Functional Class III or IV\n6. Patient willing to participate in study and provide signed IRB\u002FEC-approved informed consent\n7. Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits\n\nExclusion Criteria:\n\n1. Severe tricuspid regurgitation\n2. Severe aortic stenosis or insufficiency\n3. Severe mitral annulus calcification\n4. Diseased mitral anterior leaflet such as flail \u002F prolapse\u002F heavy calcification\n5. Implanted vena cava filter\n6. Femoral veins with severe angulation and calcification\n7. Contraindication for transesophageal echocardiography (TEE) or MDCT scan\n8. Active infection or endocarditis\n9. Previous mitral valve surgery\n10. Prior orthotopic heart transplantation\n11. Pulmonary artery systolic hypertension \\> 70mmHg\n12. Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus\n13. Left ventricular ejection fraction (LVEF) \\\u003C 30%\n14. Implant or revision of any pacing device \\\u003C 30 days prior to intervention\n15. Symptomatic coronary artery disease treated \\\u003C 30 days prior to study procedure\n16. Myocardial infarction requiring intervention \\\u003C 30 days prior to study procedure\n17. Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis\n18. Active peptic ulcer or upper gastrointestinal bleeding \\\u003C 90 days prior to study procedure\n19. Stroke \\\u003C 180 days prior to study procedure\n20. Severe renal insufficiency (creatinine \\> 3.0 mg\u002FdL) or patient requiring dialysis\n21. Cardiogenic shock at time of enrolment\n22. Hemodynamic instability requiring inotropic support or mechanical heart assistance\n23. Concurrent medical condition with a life expectancy of less than 2 years\n24. Pregnancy at time of enrolment\n25. History of bleeding diathesis or coagulopathy or leukopenia (WBC \\\u003C 3,000 mcL) or acute anemia (Hb \\\u003C 9 g\u002FdL) or thrombocytopenia (platelets \\\u003C 50,000 cells mcL)\n26. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated\n27. Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial\u002Fprocedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments\n28. Emergency situations\n29. Company employees or their immediate family members\n30. Patient is under guardianship\n31. Patient is participating in another clinical study for which follow-up is currently ongoing","18 Years",{"count":50,"type":21},10,[24],"An early feasibility study to evaluate the safety and feasibility of the MRace Implant and Delivery System to treat severe mitral regurgitation and to gather preliminary data on its performance thereby providing guidance for future clinical development. The study is a single-arm registry with the last follow-up visit at 5 years post-intervention. The study will enroll up to 10 patients at one (1) center in Brazil.",[54],"Mitral Valve Disease","2023-11-09",{"date":57,"type":32},"2023-11-13",{"date":59,"type":21},"2023-12",{"date":61,"type":21},"2029-12",{"name":38,"class":39},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100414676","explore-fmr-early-feasibility-study-of-the-plar-implant-and-delivery-system-to-treat-functional-mitral-regurgitation-100414676","NCT04679714","EXPLORE FMR: Early Feasibility Study of the PLAR Implant and Delivery System to Treat Functional Mitral Regurgitation","Early Feasibility Study of the PLAR Implant and Delivery System to Treat Functional Mitral Regurgitation (EXPLORE FMR)","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Greater than moderate functional mitral regurgitation (Grade 3+ or higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to study procedure\n3. Patient must present with an STS Score less than 10%\n4. High surgical risk for conventional mitral repair or replacement due to morphological criteria (e.g. leaflet or annulus calcifications), but operable, as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure\n5. New York Heart Association (NYHA) Functional Class III or IV\n6. Patient willing to participate in study and provide signed IRB\u002FEC-approved informed consent\n7. Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits\n\nExclusion Criteria:\n\n1. Severe tricuspid regurgitation\n2. Severe aortic stenosis or insufficiency\n3. Severe mitral annulus calcification\n4. Diseased mitral anterior leaflet such as flail \u002F prolapse\u002F heavy calcification\n5. Implanted vena cava filter\n6. Femoral veins with severe angulation and calcification\n7. Contraindication for transesophageal echocardiography (TEE) or MDCT scan\n8. Active infection or endocarditis\n9. Previous mitral valve surgery\n10. Prior orthotopic heart transplantation\n11. Pulmonary artery systolic hypertension \\> 70mmHg\n12. Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus\n13. Left ventricular ejection fraction (LVEF) \\\u003C 30%\n14. Implant or revision of any pacing device \\\u003C 30 days prior to intervention\n15. Symptomatic coronary artery disease treated \\\u003C 30 days prior to study procedure\n16. Myocardial infarction requiring intervention \\\u003C 30 days prior to study procedure\n17. Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis\n18. Active peptic ulcer or upper gastrointestinal bleeding \\\u003C 90 days prior to study procedure\n19. Stroke \\\u003C 180 days prior to study procedure\n20. Severe renal insufficiency (creatinine \\> 3.0 mg\u002FdL) or patient requiring dialysis\n21. Cardiogenic shock at time of enrolment\n22. Hemodynamic instability requiring inotropic support or mechanical heart assistance\n23. Concurrent medical condition with a life expectancy of less than 2 years\n24. Pregnancy at time of enrolment\n25. History of bleeding diathesis or coagulopathy or leukopenia (WBC \\\u003C 3,000 mcL) or acute anemia (Hb \\\u003C 9 g\u002FdL) or thrombocytopenia (platelets \\\u003C 50,000 cells mcL)\n26. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated\n27. Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial\u002Fprocedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments\n28. Emergency situations\n29. Company employees or their immediate family members\n30. Patient is under guardianship\n31. Patient is participating in another clinical study for which follow-up is currently ongoing",{"count":50,"type":21},[24],"An early feasibility study to evaluate the safety and feasibility of the PLAR Implant and Delivery System to treat severe functional mitral regurgitation and to gather preliminary data on its performance thereby providing guidance for future clinical development. The study is a single-arm registry with the last follow-up visit at 5 years post-intervention. The study will enroll up to 10 patients at one (1) center in Brazil.",[75],"Functional Mitral Regurgitation","2020-12-21",{"date":78,"type":32},"2020-12-22",{"date":80,"type":21},"2021-03",{"date":82,"type":21},"2026-12",{"name":38,"class":39},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":99,"locationsCount":4},"100414672","explore-dmr-early-feasibility-study-of-the-plar-implant-and-delivery-system-to-treat-degenerative-mitral-regurgitation-100414672","NCT04679662","EXPLORE DMR: Early Feasibility Study of the PLAR Implant and Delivery System to Treat Degenerative Mitral Regurgitation","Early Feasibility Study of the PLAR Implant and Delivery System to Treat Degenerative Mitral Regurgitation (EXPLORE DMR)","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Greater than moderate degenerative mitral regurgitation (Grade 3+ or higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to study procedure\n3. Patient must present with an STS Score less than 10%\n4. High surgical risk for conventional mitral repair or replacement due to morphological criteria (e.g. leaflet or annulus calcifications), but operable, as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure\n5. New York Heart Association (NYHA) Functional Class III or IV\n6. Patient willing to participate in study and provide signed IRB\u002FEC-approved informed consent\n7. Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits\n\nExclusion Criteria:\n\n1. Severe tricuspid regurgitation\n2. Severe aortic stenosis or insufficiency\n3. Severe mitral annulus calcification\n4. Diseased mitral anterior leaflet such as flail \u002F prolapse\u002F heavy calcification\n5. Implanted vena cava filter\n6. Femoral veins with severe angulation and calcification\n7. Contraindication for transesophageal echocardiography (TEE) or MDCT scan\n8. Active infection or endocarditis\n9. Previous mitral valve surgery\n10. Prior orthotopic heart transplantation\n11. Pulmonary artery systolic hypertension \\> 70mmHg\n12. Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus\n13. Left ventricular ejection fraction (LVEF) \\\u003C 30%\n14. Implant or revision of any pacing device \\\u003C 30 days prior to intervention\n15. Symptomatic coronary artery disease treated \\\u003C 30 days prior to study procedure\n16. Myocardial infarction requiring intervention \\\u003C 30 days prior to study procedure\n17. Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis\n18. Active peptic ulcer or upper gastrointestinal bleeding \\\u003C 90 days prior to study procedure\n19. Stroke \\\u003C 180 days prior to study procedure\n20. Severe renal insufficiency (creatinine \\> 3.0 mg\u002FdL) or patient requiring dialysis\n21. Cardiogenic shock at time of enrolment\n22. Hemodynamic instability requiring inotropic support or mechanical heart assistance\n23. Concurrent medical condition with a life expectancy of less than 2 years\n24. Pregnancy at time of enrolment\n25. History of bleeding diathesis or coagulopathy or leukopenia (WBC \\\u003C 3,000 mcL) or acute anemia (Hb \\\u003C 9 g\u002FdL) or thrombocytopenia (platelets \\\u003C 50,000 cells mcL)\n26. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated\n27. Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial\u002Fprocedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments\n28. Emergency situations\n29. Company employees or their immediate family members\n30. Patient is under guardianship\n31. Patient is participating in another clinical study for which follow-up is currently ongoing",{"count":50,"type":21},[24],"An early feasibility study to evaluate the safety and feasibility of the PLAR Implant and Delivery System to treat severe degenerative mitral regurgitation and to gather preliminary data on its performance thereby providing guidance for future clinical development. The study is a single-arm registry with the last follow-up visit at 5 years post-intervention. The study will enroll up to 10 patients at one (1) center in Brazil.",[95],"Degenerative Mitral Valve Disease",{"date":78,"type":32},{"date":80,"type":21},{"date":82,"type":21},{"name":38,"class":39},""]